Cover COVER .......& COVER
Given the value of the company compared to where it once was, it certainly is possible that a larger biotechnology firm may wish to acquire Ariad Pharmaceuticals at this bargain valuation.............
ICLUSIG is back in the Market
Iclusig is now indicated for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome-positive acute lymphoblastic
Friday Closing $10 ....Next Friday could this be $15 as Alex Denner takes the Board of Directors.
Novartis(ABL001 )-just a preclinical studies nothing has been prooved on human trials.
Considering the best best clinical results we don't see ABL001 to be in the Market before 2019.
Hedge fund operator
Carl Icahn may have received most of the credit, and certainly the lion's share of the cash, created by his high-profile biotech raiding parties. But Alex Denner has been credited as the power behind the throne, a key player in the turnaround story of several top life sciences companies and a figure now promising to start stealing his own headlines now that he's jumped Icahn's ship to helm his own hedge fund.
The two came together at ImClone after both recognized the substantial amount of money that could be made by turning around the troubled company--after CEO Sam Waksal wound up in prison after the notorious insider trading scandal. Denner headed the executive committee that held the wheel, pushing a lead experimental drug--ramucirumab--from Phase I right into late-stage studies. And he helped engineer the $6.5 billion sale to Eli Lilly ($LLY) when everyone could focus on the value of Erbitux and its experimental cancer treatments.
OGXI has agreed to pay ISIS roughly one-third of the revenue generated from these drugs. Critically, OGXI has OGX-011 - if it is successful in the current Phase III trials, it will likely be useful in treating a wide variety of different cancers. OGX-011 may represent the first of an entirely new class of cancer treatments, which would complement rather than compete with existing treatments. OGXI is well positioned to develop this drug class, with a second drug already in eight Phase II trials and a third in preclinical development. With strong intellectual property and potentially immense sales, OGXI has tremendous blue-sky potential.
Before or on 20th Feb if Alex Denner onboard, it is for sure Lilly's doors are opened.
Billionair Carl Icahn right hand man Alex Denner coming soon on Board of Directors seats.
Going to be huge as present Mkt cap is very low
OncoGenex Pharmaceuticals (OGXI) announced that the pre- specified number of events required for final analysis of the Phase 3 SYNERGY trial has been reached. The primary efficacy endpoint of SYNERGY will analyze overall survival benefit for custirsen in combination with standard first-line docetaxel chemotherapy and prednisone in men with metastatic castrate-resistant prostate cancer.
Sarissa Capital Management LP, an activist fund run by Alex Denner - investor Carl Icahn's former healthcare lieutenant - disclosed in October that it has taken a 6.2 percent stake in Ariad, becoming the company's second-largest shareholder.
Sarissa has spoken to the biotechnology company about adding a few of its own directors to the board and is interested in reaching a settlement before a proxy deadline, the people said, asking not to be named because the matter is private.
The deadline for nominating a slate of directors to Ariad's board is Feb. 20.
Iclusig vs gleevec
13 Feb 2014 ..Results : CML clinical trials at the Knight Cancer Institute at the Oregon Health & Science University (OHSU) and partners with Dr Druker.
comparing Iclusig to Gleevec, patients with newly-diagnosed cml. It is the only drug that can treat patients with the dreaded T315I mutation.
If Teva successfully commercializes Custirsen it would mark a win for Isis Pharmaceuticals (NASDAQ: ISIS ) . Why? Custirsen was developed using Isis' second-generation antisense technology and is licensed from the company. As a result, if Custirsen makes it to market, Isis stands to collect a mid-single-digit percentage of sales in royalties.
Approval would also help small-cap biotech Oncogenex, a micro-cap drug company that initially licensed Custirsen from Isis before partnering with the deeper-pocketed Teva on development.
Potential beyond prostate
Because Custirsen's action targets the clusterin protein -- and that protein is over-expressed in other cancers including lung, breast and bladder -- Teva may have opportunity to market the drug for other lucrative indications, too.
As a result, Teva has a phase 3 trial studying Custirsen as a treatment for non-small-cell lung cancer. That trial, named Enspirit, began enrollment late last year. Like in the prostate cancer trial, Custirsen is dosed alongside docetaxol. The drug showed promise in phase 2 trials, where median survival for treated patients was 14.1 months. If the drug produces similar results in phase 3, it could increase the addressable market markedly given that non-small-celll lung cancer accounts for 85% of all lung cancers.